Market Closed -
Nasdaq
21:30:01 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
6.07
USD
|
-0.16%
|
|
-10.07%
|
+57.25%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
328.5
|
63.03
|
139.7
|
263.1
|
-
|
-
|
Enterprise Value (EV)
1 |
328.5
|
63.03
|
139.7
|
263.1
|
263.1
|
263.1
|
P/E ratio
|
-1.09
x
|
-1.1
x
|
-3.68
x
|
-4.27
x
|
-4.33
x
|
-4.12
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
3.84
x
|
7.01
x
|
36.1
x
|
17
x
|
15.8
x
|
EV / Revenue
|
-
|
3.84
x
|
7.01
x
|
36.1
x
|
17
x
|
15.8
x
|
EV / EBITDA
|
-6.59
x
|
-1.15
x
|
-3.61
x
|
-3.8
x
|
-2.98
x
|
-
|
EV / FCF
|
-7.57
x
|
-1.43
x
|
-4.19
x
|
-4.94
x
|
-5.98
x
|
-5.1
x
|
FCF Yield
|
-13.2%
|
-70.1%
|
-23.9%
|
-20.3%
|
-16.7%
|
-19.6%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
27,579
|
30,745
|
36,192
|
43,347
|
-
|
-
|
Reference price
2 |
11.91
|
2.050
|
3.860
|
6.070
|
6.070
|
6.070
|
Announcement Date
|
24/03/22
|
23/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
16.4
|
19.94
|
7.287
|
15.47
|
16.67
|
EBITDA
1 |
-
|
-49.87
|
-54.95
|
-38.74
|
-69.32
|
-88.3
|
-
|
EBIT
1 |
-22.4
|
-50.09
|
-56.06
|
-40.5
|
-73.45
|
-70.91
|
-83.14
|
Operating Margin
|
-
|
-
|
-341.78%
|
-203.09%
|
-1,007.93%
|
-458.25%
|
-498.85%
|
Earnings before Tax (EBT)
1 |
-
|
-49.98
|
-53.81
|
-37.37
|
-73.9
|
-63.21
|
-83.28
|
Net income
1 |
-
|
-201.9
|
-53.81
|
-37.37
|
-73.9
|
-68.23
|
-83.28
|
Net margin
|
-
|
-
|
-328.09%
|
-187.37%
|
-1,014.17%
|
-440.92%
|
-499.66%
|
EPS
2 |
-3.240
|
-10.94
|
-1.860
|
-1.050
|
-1.420
|
-1.402
|
-1.475
|
Free Cash Flow
1 |
-
|
-43.37
|
-44.21
|
-33.38
|
-53.28
|
-43.97
|
-51.58
|
FCF margin
|
-
|
-
|
-269.54%
|
-167.38%
|
-731.21%
|
-284.16%
|
-309.48%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/02/21
|
24/03/22
|
23/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
4.148
|
4.97
|
7.283
|
4.464
|
8.081
|
5.897
|
1.501
|
0.742
|
1.822
|
1.822
|
1.822
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3.703
|
-6.709
|
-12.5
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.8
|
-17.88
|
-15.37
|
-14.97
|
-12.54
|
-13.18
|
-12.22
|
-6.067
|
-9.251
|
-12.96
|
-17.16
|
-18.33
|
-18.76
|
-19.2
|
-
|
Operating Margin
|
-
|
-
|
-
|
-360.95%
|
-252.29%
|
-180.96%
|
-273.81%
|
-75.08%
|
-156.88%
|
-863.56%
|
-2,312.94%
|
-1,005.98%
|
-1,029.69%
|
-1,054.01%
|
-
|
Earnings before Tax (EBT)
1 |
-13.76
|
-17.87
|
-15.34
|
-14.59
|
-11.94
|
-11.93
|
-11.98
|
-5.098
|
-8.285
|
-12
|
-16.19
|
-18.7
|
-
|
-19.96
|
-
|
Net income
1 |
-13.76
|
-17.87
|
-15.34
|
-14.59
|
-11.94
|
-11.93
|
-11.98
|
-5.098
|
-8.285
|
-12
|
-16.19
|
-18.7
|
-19.05
|
-19.96
|
-
|
Net margin
|
-
|
-
|
-
|
-351.83%
|
-240.3%
|
-163.81%
|
-268.41%
|
-63.09%
|
-140.5%
|
-799.67%
|
-2,182.35%
|
-1,026.62%
|
-1,045.72%
|
-1,095.5%
|
-
|
EPS
2 |
-0.5100
|
-0.6600
|
-0.5600
|
-0.5300
|
-0.4000
|
-0.3900
|
-0.3400
|
-0.1400
|
-0.2300
|
-0.3300
|
-0.3900
|
-0.3540
|
-0.2125
|
-0.3760
|
-0.4700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
24/03/22
|
10/05/22
|
11/08/22
|
10/11/22
|
23/03/23
|
11/05/23
|
10/08/23
|
14/11/23
|
07/03/24
|
03/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-43.4
|
-44.2
|
-33.4
|
-53.3
|
-44
|
-51.6
|
ROE (net income / shareholders' equity)
|
-400%
|
-39.1%
|
-32%
|
-65.6%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-2.320
|
-1.410
|
-0.9100
|
-2.220
|
-1.710
|
-
|
Capex
1 |
-
|
3.61
|
0.77
|
7.64
|
9.14
|
11.8
|
Capex / Sales
|
-
|
22.02%
|
3.86%
|
104.84%
|
59.07%
|
70.68%
|
Announcement Date
|
24/03/22
|
23/03/23
|
07/03/24
|
-
|
-
|
-
|
Last Close Price
6.07
USD Average target price
12.5
USD Spread / Average Target +105.93% Consensus |
1st Jan change
|
Capi.
|
---|
| +57.25% | 263M | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|